RxDoctor Payments Data

Nandita Gatla, MD

Rheumatology · Portsmouth, OHNPI 1306166632

Payments from drug & device makers

$1,518in general payments, 2019–2025

Across 108 payments — averaging $14.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$498
  • Novartis$202
  • Johnson & Johnson$135
  • Radius Health, Inc.$108
  • GSK$86
  • UCB, Inc.$85
  • plus $404 from 11 others

What the payments were for

  • Consulting fees$403%
  • Food & beverage$1,42394%
  • Education$554%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,518 in reported general payments places this provider in the 50th percentile of 255 rheumatology providers in Ohio.

See all rheumatology providers in Ohio

Medicare billing

Part B allowed, 2024
$25,575
Medicare patients
190
Services billed
246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept75$592,677
Cyltezo(Cf) PenAdalimumab-Adbm87$581,823
Humira(Cf) PenAdalimumab53$375,371
RinvoqUpadacitinib46$312,918
Skyrizi PenRisankizumab-Rzaa15$305,003
TremfyaGuselkumab22$294,811
Xeljanz XrTofacitinib Citrate22$125,316
Enbrel MiniEtanercept13$108,797
Cosentyx Sensoready (2 Pens)Secukinumab15$107,360
OtezlaApremilast20$93,616
ForteoTeriparatide15$61,606
ProliaDenosumab30$51,038
Leflunomide91$7,021
Hydroxychloroquine Sulfate155$6,355
MethotrexateMethotrexate Sodium215$6,101

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$135$294,81122 claims
AmgenOtezla, Prolia$498$144,65450 claims
Lilly USA, LLCForteo$81$61,60615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 255 rheumatology providers in Ohio.

Other rheumatology in Portsmouth

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →